Neurology
Our Specialists
Neurology
Kathleen A. Maguire-Zeiss, Ph.D.
585-273-1503 (office)
585-273-2198 (lab)
Current Titles and Roles
2002- present; Research Assistant Professor (Center for Aging & Developmental
Biology)
Degrees, Certifications,
and Licenses
-
B.S., Biochemistry, Albright College
-
Ph.D., Pharmacology, Pennsylvania
State University College of Medicine
-
Post-doctoral training, University
of Pennsylvania, The Wistar Institute of Anatomy & Biology
Prior Work History
1997-2002; Associate, Neurology, Center for Aging & Developmental
Biology, University of Rochester of Medicine & Dentistry
1996-1997; Senior Instructor, Neurology, Center for Aging & Developmental
Biology, University of Rochester of Medicine & Dentistry
1993-1996;
Senior Instructor, Neurology, Geriatric Neurology Unit, University
of Rochester of Medicine & Dentistry
1990-1993; Instructor,
Neurology, Geriatric Neurology Unit, University of Rochester
School of Medicine & Dentistry
Highlights
- Member Society of Neuroscience
- Member American Society of Gene
Therapy
- Member Sigma Xi Research Society
- NIH Individual National Research
Service Award, National Cancer Institute, 1987-1990
- Markey Foundation
Pilot Grant, “Regulation of Calbindin
D-28k Expression”, 1991-1992
- Alzheimer's Association Pilot
Research Grant, “Calcium
binding proteins in Alzheimer’s Disease”, 1991-1992
- American
Health Assistance Foundation Alzheimer's Research Grant, "Calbindin
D28k: Distribution & Regulation in AD", 1992-1995
- Rochester
Alzheimer's Disease Center Pilot, "Estrogen Receptor
mRNA in AD", 1995-1996
Research
“Development and Application of Single Chain Antibodies
for PD Therapy”
Principle Investigator: Howard J. Federoff, M.D., Ph.D.
Co-Investigator: Kathleen Maguire-Zeiss, Ph.D.
Project Number: DAMD17-02-1-0695
Source: DOD Dates of Approved/Proposed Project: 08/01/02-07/31/07
Parkinson’s disease affects over one million Americans and
is the second leading neurodegenerative disease. The etiology of
Parkinson’s disease is currently unknown but is thought to
involve both genetic and environmental triggers. Despite multiple
initiating factors, we and others envisage a common pathobiologic
model of Parkinson’s disease. Sporadic and genetic forms
of Parkinson’s disease display the profound loss of nigrostriatal
dopamine neurons and the hallmark pathological feature of intracytoplasmic
inclusions called Lewy bodies, comprised of a number of proteins
including ?-synuclein. We are investigating the role of dopamine
and ?-synuclein in the pathogenesis of Parkinson’s disease.
Utilizing both in vitro and in vivo models of Parkinson’s
disease we are studying the role of protein aggregation in this
neurodegenerative disease. One of the major goals of this project
is to establish the utility of single-chain antibody treatment
for the attenuation of ?-synuclein aggregation, a posited convergent
mechanism of Parkinson's disease pathophysiology.
Academic Activity
- Lecturer, MBB II: Advanced Basic Sciences, Development & Degeneration:
A Life-Long Balance Influencing Brain Function: 2002-Ongoing.
- Lecturer,
Neuroscience Investigative Seminars, Department of Neurosurgery:
2001.
- Faculty facilitator, Ethics and Professional Integrity
(IND 501, CRN 51942): 2001-2003.
- Thesis Committee Member
- Thesis Co-Advisor
- Member Grant Peer Review Panel, American Institute of Biological
Sciences, Neurotoxin Exposure & Treatment Research Program-2002
- Ad Hoc
Reviewer, Neurobiology of Aging
|
